1319738-33-4

Basic information

• Product Name: (1'S,3R/S)-1-(1'-(4-methoxyphenyl)ethyl)-5-oxo-3-pyrrolidine carboxylic acid
• Synonyms: (1'S,3R/S)-1-(1'-(4-methoxyphenyl)ethyl)-5-oxo-3-pyrrolidine carboxylic acid
• CAS NO: 1319738-33-4
• Molecular Weight: 263.293
• Mol File: 1319738-33-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (1'S,3R/S)-1-(1'-(4-methoxyphenyl)ethyl)-5-oxo-3-pyrrolidine carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1'S,3R/S)-1-(1'-(4-methoxyphenyl)ethyl)-5-oxo-3-pyrrolidine carboxylic acid(1319738-33-4)
• EPA Substance Registry System: (1'S,3R/S)-1-(1'-(4-methoxyphenyl)ethyl)-5-oxo-3-pyrrolidine carboxylic acid(1319738-33-4)

Safety Data

• Hazardous Substances Data: 1319738-33-4(Hazardous Substances Data)

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 6298-96-0 (S)-1-(4-methoxyphenyl)ethylamine 

Downstream Products

• 1319738-34-5 (R/S)-N-methoxy-5-oxo-1-[(S)-1-(4-methoxyphenyl)-ethyl]-pyrrolidine-3-carboxamide 

Relevant articles and documents

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

HETEROARYL SYK INHIBITORS

The invention relates to new substituted heteroarylsof formula (1) wherein A is selected from the group consisting of N and CH, D is selected from the group consisting of S and O, E is C, T is C, G is C, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted quinolines of formula (1) wherein R1 is a linear or branched C1-6-alkyl, wherein R1 may optionally be substituted by R3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R3 may optionally be substituted further substituted as defined in claim 1 and wherein R2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; a bicyclic, nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R2 may optionally be further substituted as defined in claim 1, and their use in the preparation of medicaments for the treatment of disease such as asthma, COPD, allergic rhinitis, allergic dermatitis and rheumatoid arthritis.